Terns Pharmaceuticals(TERN) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR- ABL) in CML expected in 2H24 "We continue to execute our strategy and make important progress on our pipeline of potential best-in-class small molecule therapies as we prepare for key data readouts from our two lead programs," said Amy Burroughs, chief executive officer of Terns, "We look forward to re ...